| Similar Articles |
|---|
 |
The Motley Fool
June 15, 2005
Charly Travers |
Flamel's CEO Must Go Because the biotech firm has disappointed, investors have understandably not rewarded its lousy results. Flamel's shareholders must vote to remove a management road block to the company's success.   |
The Motley Fool
September 6, 2005
Rich Duprey |
Flamel's Dubious Future French nanotech pioneer loses deal with TAP Pharmaceuticals for heartburn formulation. There's just too much fog facing this company for investors to see clearly ahead. |
The Motley Fool
June 14, 2005
Bill Mann |
It's Time for a Change at Flamel A dissident shareholder believes that the French medical tech company's management needs shaking up. Reluctantly, we agree. |
The Motley Fool
March 4, 2005
Rich Duprey |
Flamel Flames Out Again Nanotech regains rights to herpes treatment as partnership with pharma Biovail fails. |
The Motley Fool
December 18, 2006
Brian Lawler |
Nice: Flamel's Drug Approval With so much pessimism and internal hullabaloo, there weren't many investors willing to stick with Flamel, but those who did have been rewarded nicely. |
The Motley Fool
October 29, 2004
W.D. Crotty |
Future Looking Up for Flamel As the nanotech/biotech company earns a profit -- keep an eye on two drugs in phase 3 trials. |
The Motley Fool
July 30, 2004
W.D. Crotty |
This Nanotech Deserves Respect While the stock recently hit some potholes, Flamel still looks good for the future. |
The Motley Fool
June 23, 2005
Bill Barker |
History Is Made, for Now At yesterday's annual meeting, Flamel's shareholders made history. All proposals to re-elect the former directors were rejected by voting shareholders. |
The Motley Fool
October 25, 2005
Jason Mac Gurn |
Visualizing Value for Flamel Those interested in the long-term potential of this biotech's business should be searching for signs that its technological potential will evolve to provide value for shareholders. |
The Motley Fool
September 27, 2005
Jack Uldrich |
A Ray of Hope for Flamel? New hepatitis C treatment offers a ray of hope to the ailing nanotech company. Unfortunately, this news does not guarantee sunnier days ahead. |
The Motley Fool
September 20, 2004
Wherrett & Yelovich |
Flamel Shot Down The company's nano product loses some of its shine. The stock fell more than 25% after Bristol-Myers Squibb pulled out of its partnership to develop Basulin. |
The Motley Fool
August 27, 2007
Rich Duprey |
Flamel Falls Out of Compliance Market lashes out after a patient-compliance study shows that its only drug offers no better solution. Flamel has always been a risky investment, and that hasn't changed. |
The Motley Fool
May 15, 2008
Brian Lawler |
What's Cooking at Flamel? The drugmaker makes finding partners to help pay for its hepatitis C and diabetes compounds a top priority. |
The Motley Fool
July 8, 2004
W.D. Crotty |
From Flameout to Bargain Despite its stock decline, there's a lot to like about French biopharmaceutical Flamel. |
The Motley Fool
March 5, 2008
Brian Lawler |
Flamel in a Nutshell After a choppy year, Flamel says there are plenty of new possibilities in its pipeline. |
The Motley Fool
September 14, 2007
Brian Lawler |
Is Flamel Catching On? Flamel Technologies announces a deal with Wyeth to develop an improved formulation of a drug, but the financials, and details, remain secret. |
The Motley Fool
August 8, 2008
Brian Lawler |
Flamel Tries to Get It in Gear Flamel has done a good job of reducing its cash burn, allowing it to buy some time to work on the compounds in its pipeline. |
The Motley Fool
November 2, 2007
Brian Lawler |
Flamel Plays Close to the Vest With only one sustainable source of revenue, the drug developer tries to curtail spending and get new compounds into the pipeline. Investors, take note. |
The Motley Fool
April 28, 2008
Brian Lawler |
Flamel Inches Forward New sales data arrives for one lead drug, new promising data for another. |
The Motley Fool
October 25, 2007
Brian Lawler |
Flamel Gets Upbeat News About Coreg Flamel Technologies is earning more than had been calculated from its lead drug, but the company still isn't profitable. Investors, take note. |
The Motley Fool
November 15, 2007
Brian Lawler |
Flamel Now Part of Wacky Lawsuit Hijinks Multiple class action shareholder lawsuits targeting Flamel Technologies are announced, following a failed study of the company's lead drug. |
The Motley Fool
January 12, 2006
Rich Duprey |
Will the SEC Trim the Hedges? As hedge funds are immersing themselves even more in mergers and acquisitions, a field that is fast approaching $1 trillion a year, it's not surprising that they will now also find themselves under closer scrutiny by regulators. |
The Motley Fool
December 21, 2007
Brian Lawler |
Flamel Wheeling and Dealing Flamel announces very few details about it's latest deal, this time with German drugmaker Merck KGaA. |
The Motley Fool
July 26, 2007
Brian Lawler |
Flamel Gets Stomped by GSK Shares of Flamel fall as its partner doesn't focus on marketing its lead drug. |
The Motley Fool
February 11, 2008
Brian Lawler |
No Fire Fueling Flamel's Top Drug Flamel Technologies had a rough 2007; and with only one drug determining its near-term success, investors should be cautious of this drugmaker. |
The Motley Fool
January 6, 2005
Rich Duprey |
Bristol-Myers Relieves Its Headache The pharmaceutical giant is selling its consumer medicines division. Though the division represents only about 2% of Bristol-Myers' $21 billion sales, the company overall has seen sales falter and its stock decline some 12% last year. |
The Motley Fool
September 26, 2007
Brian Orelli |
4 Platform Drugmakers to Watch Platform drugmakers have the potential to develop multiple drugs for a company. Let's take a look at four companies with good prospects: Abraxis BioScience... DURECT... Halozyme... Flamel Technologies... |
The Motley Fool
November 26, 2007
Brian Lawler |
Glaxo Goes Holiday Shopping The pharmaceutical giant snaps up another acquisition, privately held Reliant Pharmaceuticals, for $1.65 billion in cash, one of the largest pharma deals of the year. |
The Motley Fool
October 26, 2007
Brian Lawler |
Another Prospect for Flamel The drug developer's good week continues with favorable news about a treatment for hepatitis C. Investors, take note. |
The Motley Fool
August 3, 2007
Brian Lawler |
Flamel Cooked When a drugmaker's future is highly dependent on one product, shares are bound to take a hit if that product isn't living up to expectations. Such was the case with Flamel Technologies. |
The Motley Fool
April 24, 2006
Rich Duprey |
CEC Under Pirate Attack Hedge fund activist Pirate Capital takes a large stake in the kid-oriented pizza-and-party operation. Investors, is this good or bad? Take note. |
The Motley Fool
May 14, 2007
Brian Lawler |
Just the Beginning for Flamel? The drug developer released first-quarter financial results and updated investors on the progress of its newly marketed Coreg CR compound. Investors, take note. |
